Reaching the unreached arrhythmia substrate in cardiomyopathies

Reaching the unreached arrhythmia substrate in cardiomyopathies

In patients with cardiomyopathies accurate elimination of the substrate for ventricular tachycardias is crucial. This is commonly performed by radiofrequency catheter ablation. In  cardiomyopathy subtypes the substrate may be difficult to reach by conventional endo- or epicardial approaches. Over the last years WECAM’s physicians and researchers have developed and applied new strategies.



Radiofrequency catheter ablation of ventricular tachycardia in nonischemic cardiomyopathy can be challenging. Stereotactic body radiotherapy is an emerging technique for these difficult ablations requiring precise substrate delineation and data transfer. Based on our longstanding experience with multimodal data integration we have developed, together with international partners, a highly accurate workflow with promising clinical results.

project radiotherapy wecam

Surgical arrhythmia treatment

Novel technologies and energy sources to increase lesion size and reach VT substrates are under investigation.

Key publications

Accuracy of electroanatomical mapping-guided cardiac radiotherapy for ventricular tachycardia: pitfalls and solutions.
Edition: 1099-5129 | Pages: 1989-1997
Integration of Electroanatomical Mapping With Imaging to Guide Radiotherapy of VT Substrates With High Accuracy.
Edition: 2405-500X | Pages: 874-876
Endocardial/epicardial versus endocardial encircling cryoablation for ventricular tachycardia: A randomized trial.
Edition: 0022-5223 | Pages: e371-e377
Programmed electrical stimulation-guided encircling cryoablation concomitant to surgical ventricular reconstruction for primary prevention of ventricular arrhythmias.
Edition: 1010-7940 | Pages: 98-105
Initial human feasibility of infusion needle catheter ablation for refractory ventricular tachycardia.
Edition: 0009-7322 | Pages: 2289-2295
Catheter ablation of ventricular tachycardia after left ventricular reconstructive surgery for ischemic cardiomyopathy.
Edition: 1547-5271 | Pages: 10-17
Scroll to Top